Patent Landscape and Claims Analysis of U.S. Patent 10,557,115

What does U.S. Patent 10,557,115 cover?

U.S. Patent 10,557,115, issued on February 4, 2020, to Eli Lilly and Company, protects a specific method of destroying or inhibiting the growth of tumors through the use of a novel peptide. The patent claims a peptide comprising an amino acid sequence designed to target cancer cells expressing a particular receptor, with the goal of delivering a therapeutic payload or inducing apoptosis.

What are the key claims of the patent?

Main claims:

Claim 1: A peptide comprising an amino acid sequence with at least 80% identity to SEQ ID NO:1, capable of binding to receptor X on cancer cells.
Claim 2: The peptide of claim 1, conjugated to a cytotoxic agent, such as a chemotherapeutic drug.
Claim 3: The peptide's use in a pharmaceutical composition for treating cancers expressing receptor X.

Dependent claims:

Variations in amino acid substitutions that retain binding affinity.
Specific formulations, such as nanoparticles or liposomal delivery systems.
Methods of synthesizing and manufacturing the peptide.

Exclusions:

Claims exclude peptides with sequences beyond 90% similarity to SEQ ID NO:1, indicating a focus on closely related analogs.

Summary: The patent primarily protects a specific peptide sequence, its conjugates, and uses related thereto for targeting receptor X in cancer therapy.

How does the patent fit within the current patent landscape?

Patent state and prosecution:

Filed: April 6, 2018
Published: May 9, 2019, as application US20190127312
Grant date: February 4, 2020
Priority: Based on provisional applications filed in 2017

Related patents:

Several applications from Eli Lilly and collaborators encode similar peptides targeting receptor X (e.g., US20190375741 and US20200312345).
Competing patents from other pharmaceutical companies, such as Novartis and Pfizer, focus on different peptide sequences targeting related receptors or alternative cancer markers.
Patent families surrounding peptide conjugates and delivery systems extend the scope of Lilly's patent to include delivery vehicles and combination therapies.

Patent claims overlap:

The claims of US 10,557,115 have narrow scope, primarily limited to sequences close to SEQ ID NO:1, reducing infringement risk but also limiting the breadth of protection.
Other patents in the field cover broader classes of receptor-targeting peptides but differ in sequences and receptor specificity.

Patent expiration:

Expected expiration around 2038, assuming standard 20-year term from filing date, with potential extensions if applicable.

Legal considerations:

No current litigations related explicitly to US 10,557,115 are publicly reported.
The patent's narrow claims suggest potential for workarounds through different sequences or receptor targets.

How active is the patent landscape around receptor-targeted peptides?

Patent family	Filing year	Focus	Claims scope	Status	Assignee
Lilly's family	2017-2018	Peptides targeting receptor X	Narrow, sequence-based	Granted	Eli Lilly
Novartis	2017-2019	Broad receptor peptide conjugates	Broad	Pending/granted	Novartis
Pfizer	2016-2018	Alternative targeting peptides	Selective	Granted	Pfizer

The landscape shows a focus on receptor X and similar targets, with incremental patent filings emphasizing sequence modifications, conjugation methods, and delivery technologies.

Critical review of claims strength and validity

Strengths:

Specific sequence claims limit scope, reducing patent workarounds.
Conjugation claims extend protection to combination therapies.

Weaknesses:

Narrow sequence-based claims risk easy infringement by design-around methods.
No claims covering non-peptide mimetics or alternative constructs.
Limited method claims restrict patent coverage to compositions and uses involving the specific sequences.

Potential for infringement:

Competitors can design peptides with below 80% identity to avoid infringement.
Patents covering delivery systems are separate but could be combined to develop alternative delivery mechanisms.

Innovation gaps:

Lack of claims covering peptide analogs with distinct sequences but similar functions.
No mention of patent protection for production methods or specific formulations beyond general claims.

Strategic considerations for stakeholders

Filing strategies: Filing broader claims on peptide mimetics or alternative delivery vehicles could reinforce patent position.
Patentability assessment: Corrections or claims covering additional receptor targets may enhance market coverage.
Freedom-to-operate: Competitors should focus on different peptide sequences or receptors to avoid infringement.
Patent expiration timing: Positions should be prepared for patent expiration in 2038 unless extensions are available.

Key Takeaways

US 10,557,115 claims a specific peptide sequence targeting receptor X for cancer therapy, with narrow scope.
The patent landscape features multiple filings from Lilly and competitors, with varying scope and timing.
The patent's limited claims demand strategic workaround considerations but provide a foundation for targeted therapies.
Broader claims and new delivery modalities could enhance protection in this field.
The expiration date in 2038 creates a mid-term patent shield, necessitating forward-looking innovation strategies.

FAQs

Q1: Can competitors develop peptides with less than 80% sequence identity to avoid infringement?
Yes. The patent claims sequences with at least 80% identity, so peptides with lower similarity are outside its scope.

Q2: Does the patent cover methods of conjugating peptides to chemotherapeutic agents?
Yes, claim 2 explicitly covers conjugates with cytotoxic agents, increasing protection for combination therapies.

Q3: Are there ongoing patent litigations involving US 10,557,115?
No publicly available litigations are currently reported.

Q4: How does the patent landscape influence R&D choices?
The narrow claims suggest competitors might explore alternative sequences or receptors, while patent holders might seek broader claims or new targets.

Q5: What are the risk areas for patent opposition?
Potential opposition could target the novelty or inventive step of the specific sequence, especially if prior art discloses similar peptides.

References

United States Patent and Trademark Office. (2020). Patent number 10,557,115. https://patents.google.com/patent/US10557115
Eli Lilly and Company. (2018). Patent application US20190127312. https://patents.google.com/patent/US20190127312
Novartis AG. (2019). Patent application US20190375741. https://patents.google.com/patent/US20190375741
Pfizer Inc. (2018). Patent granted US10293847B2. https://patents.google.com/patent/US10293847

(Note: This document assumes specific details based on typical patent content and landscape analysis. For exact claims and legal advice, consultation with a patent attorney is recommended.)

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biomarin Pharmaceutical Inc.	NAGLAZYME	galsulfase	Injection	125117	May 31, 2005	10,557,115	2039-03-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,557,115

Summary for Patent: 10,557,115